Amelia Insa
A5022853691- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Cytokine Signaling Pathways and Interactions
- Synthesis and biological activity
- Cancer Treatment and Pharmacology
- Immunotherapy and Immune Responses
- Peptidase Inhibition and Analysis
- Chemokine receptors and signaling
- Radiomics and Machine Learning in Medical Imaging
- Lymphoma Diagnosis and Treatment
- Brain Metastases and Treatment
- DNA Repair Mechanisms
- BRCA gene mutations in cancer
- Neuroendocrine Tumor Research Advances
- Gastric Cancer Management and Outcomes
- Esophageal Cancer Research and Treatment
- HER2/EGFR in Cancer Research
- Cancer therapeutics and mechanisms
- Breast Cancer Treatment Studies
- PARP inhibition in cancer therapy
- Melanoma and MAPK Pathways
Hospital Clínico Universitario de Valencia
2016-2025
INCLIVA Health Research Institute
2019-2025
Institut Català d'Oncologia
2007-2023
Hospital Universitario Puerta de Hierro Majadahonda
2023
Hospital Universitario La Paz
2023
Centro de Investigación del Cáncer
2023
Instituto Oncológico Dr. Rosell
2023
Hospital Clínico Universitario de Valladolid
2023
Instituto de Investigación Biomédica de Málaga
2023
Universitat de València
2003-2021
Activating mutations in the epidermal growth factor receptor gene (EGFR) confer hypersensitivity to tyrosine kinase inhibitors gefitinib and erlotinib patients with advanced non–small-cell lung cancer. We evaluated feasibility of large-scale screening for EGFR such analyzed association between outcome treatment.
Advanced non-small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations (deletion in exon 19 or L858R) show an impressive progression-free survival of 14 months when treated with erlotinib. However, the presence EGFR can only imperfectly predict outcome. We hypothesized that could be influenced both by pretreatment T790M mutation and components DNA repair pathways.We assessed diagnostic specimens from 129 erlotinib-treated advanced NSCLC mutations....
Approximately 20% of patients with non-small-cell lung cancer (NSCLC) receive a diagnosis stage III disease. There is no current consensus regarding the most appropriate treatment for these patients.In this open-label, phase 2 trial, we randomly assigned resectable IIIA or IIIB NSCLC to neoadjuvant nivolumab plus platinum-based chemotherapy (experimental group) alone (control group), followed by surgery. Patients in experimental group who had R0 resections received adjuvant 6 months. The...
Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in resectable non-small-cell lung cancer (NSCLC) the NADIM trial (ClinicalTrials.gov identifier: NCT03081689). The 3-year overall survival (OS) and circulating tumor DNA (ctDNA) analysis have not reported.This was an open-label, multicenter, single-arm, phase II which patients with stage IIIA NSCLC, who were deemed surgically resectable, treated neoadjuvant paclitaxel (200 mg/m2 once a day) carboplatin (area under curve...
The EURTAC trial demonstrated the greater efficacy of erlotinib compared with chemotherapy for first-line treatment European patients advanced non-small-cell lung cancer (NSCLC) harboring oncogenic epidermal growth factor receptor (EGFR) mutations (exon 19 deletion or L858R mutation in exon 21) tumor tissue.To assess feasibility using circulating free DNA (cfDNA) from blood samples as a surrogate biopsy determining EGFR status and to correlate cfDNA outcome.This prespecified analysis was...
To evaluate the dose-response effect of an adjuvant anthracycline-based non-taxane chemotherapy in early breast cancer patients. This was a retrospective database analysis. Selection criteria included patients treated for from years 1980 to 2000 with chemotherapy. The delivery assessed through number delayed cycles, days and relative dose intensity (RDI) administered (>or= 85%, <85%). Seven hundred ninety-three were included. Kaplan-Meier disease-free survival (DFS) affected by cycles...
Non-small cell lung cancer (NSCLC) accounts for up to 85% of all cancers. The last few years have seen the development a new staging system, diagnostic procedures such as liquid biopsy, treatments like immunotherapy, well deeper molecular knowledge; so, more options can be offered patients with driver mutations. Groups specific account around 25% and demonstrate significant increases in overall survival, some subgroups, it is important evaluate each treatment alternative accordance...
7503 Background: EGFR tyrosine kinase activating mutations are present in 10-26% of NSCLC tumors and associated with increased response to gefitinib erlotinib. However, little is known about how the efficacy safety profile erlotinib compares CT EGFR-mutant Caucasian p. We have performed a prospective, randomized phase III study comparing platinum-based chemonaive advanced p mutations. Methods: From February 2007 January 2011, we screened 1,227 for mutations, 174 patients were randomly...
8501 Background: Non-small cell lung cancer (NSCLC) is incurable in most patients with locally advanced stage IIIA disease. Previous results indicate that the use of neoadjuvant chemoimmunotherapy could increase percentage cured being a promising therapeutic option has to be tested randomized clinical trials. Methods: NADIM II (NCT03838159) an open-label, randomized, two-arm, phase II, multi-center trial. Patients resectable (per AJCC 7 th ed) NSCLC, ECOG PS 0-1, and no known EGFR/ALK...
Neoadjuvant chemoimmunotherapy for non-small cell lung cancer (NSCLC) has improved pathological responses and survival rates compared with chemotherapy alone, leading to Food Drug Administration (FDA) approval of nivolumab plus resectable stage IB-IIIA NSCLC (AJCC 7th edition) without ALK or EGFR alterations. Unfortunately, a considerable percentage tumors do not completely respond therapy, which been associated early disease progression. So far, it is impossible predict these events due...
The aim of this study was to determine independent clinical and pathological prognostic factors for overall disease-free survival in Spanish melanoma patients. Eight hundred twenty-three patients with localized complete information were evaluated. age at diagnosis, gender, location, tumour thickness, invasion level, ulceration, histological subtype, inflammatory infiltrate, mitotic rate, vascular invasion, microscopic satellitosis, regression cell type all included. Univariate multivariate...
To assess the activity of induction chemotherapy followed by surgery in stage IIIA and selected IIIB non-small-cell lung cancer patients.Mediastinoscopy proof either positive N2 (IIIA) or T4N0-1 (IIIB) disease was required. Induction therapy three cycles cisplatin/gemcitabine/docetaxel, surgery.From December 1999 to March 2003, 136 patients were entered onto study; clinical response rate 129 assessable 56%. The overall complete resection 68.9% eligible for (72% 66% patients) 48% all...
8521 Background: The combination of chemotherapy and immunotherapy (CT-IO) has a high response rate longer survival in unselected patients (pts) with metastatic non-small cell lung cancer (NSCLC). There are no data about this the neoadjuvant setting. Methods: A Phase II, single-arm, open-label multicenter study resectable stage IIIA N2-NSCLC adult CT plus IO (nivolumab (NV)) followed by adjuvant treatment for 1 year. Neoadjuvant treatment: Three cycles NV 360mg IV Q3W + paclitaxel 200mg/m2...
IntroductionThe ROS1 gene rearrangement has become an important biomarker in NSCLC. The College of American Pathologists/International Association for the Study Lung Cancer/Association Molecular Pathology testing guidelines support use immunohistochemistry (IHC) as a screening test, followed by confirmation with fluorescence situ hybridization (FISH) or molecular test all positive results. We have evaluated novel anti-ROS1 IHC antibody (SP384) large multicenter series to obtain real-world...
8509 Background: Patients with stage IIIA (N2 or T4N0) are potentially curable but median overall survival is only around 15 months and complete pathologic response conventional chemotherapy (CT) no more than 9%. Methods: A Phase II, single-arm, open-label multicenter study of resectable N2-NSCLC adult patients CT plus IO as a neoadjuvant treatment: three cycles Nivolumab (NV) 360mg IV Q3W + paclitaxel 200mg/m2 carboplatin AUC 6 followed by adjuvant NV treatment for 1 year. After therapy,...
Abstract Although EGFR mutant–selective tyrosine kinase inhibitors (TKI) are clinically effective, acquired resistance can occur by reactivating ERK. We show using in vitro models of TKI with a mesenchymal phenotype that CXCR7, an atypical G protein-coupled receptor, activates the MAPK–ERK pathway via β-arrestin. Depletion CXCR7 inhibited MAPK pathway, significantly attenuated resistance, and resulted mesenchymal-to-epithelial transition. overexpression was essential reactivation ERK1/2 for...
Abstract Purpose: Characterization of the T-cell receptor (TCR) repertoire may be a promising source for predictive biomarkers pathologic response to immunotherapy in locally advanced non–small cell lung cancer (NSCLC). Experimental Design: In this study, next-generation TCR sequencing was performed peripheral blood and tissue samples 40 patients with NSCLC, before after neoadjuvant chemoimmunotherapy (NADIM clinical trial, NCT03081689), considering their complete (CPR) or non-CPR. Beyond...